Parkinson's disease stopped in animal model
March 2, 2012 By Mark Wheeler in Parkinson's & Movement disorders
(Medical Xpress) -- Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.
While it's not known what exactly causes the disease, evidence points to one particular culprit: a protein called α-synuclein. The protein, which has been found to be common to all patients with Parkinson's, is thought to be a pathway to the disease when it binds together in "clumps," or aggregates, and becomes toxic, killing the brain's neurons.
Now, scientists at UCLA have found a way to prevent these clumps from forming, prevent their toxicity and even break up existing aggregates.
UCLA professor of neurology Jeff Bronstein and UCLA associate professor of neurology Gal Bitan, along with their colleagues, report the development of a novel compound known as a "molecular tweezer," which in a living animal model blocked α-synuclein aggregates from forming, stopped the aggregates' toxicity and, further, reversed aggregates in the brain that had already formed. And the tweezers accomplished this without interfering with normal brain function.
The research appears in the current online edition of the journal Neurotherapeutics.
There are currently more than 30 diseases with no cure that are caused by protein aggregation and the resulting toxicity to the brain or other organs, including Parkinson's, Alzheimer's and Type 2 diabetes. It is therefore critical, Bronstein said, to find a way to stop this aggregation process. Over the last two decades, researchers and pharmaceutical companies have attempted to develop drugs that would prevent abnormal protein aggregation, but so far, they have had little or no success.
While these aggregates are a natural target for a drug, finding a therapy that targets only the aggregates is a complicated process, Bronstein said. In Parkinson's, for example, the protein implicated in the disorder, α-synuclein, is naturally ubiquitous throughout the brain.
"Its normal function is not well understood, but it may play a role in aiding communication between neurons," Bronstein said. "The trick, then, is to prevent the α-synuclein protein aggregates and their toxicity without destroying α-synuclein's normal function, along with, of course, other healthy areas of the brain.
Molecular tweezer
Bronstein collaborated with Bitan, who had been working with a particular molecular tweezer he had developed called CLR01. Molecular tweezers are complex molecular compounds that are capable of binding to other proteins. Shaped like the letter "C," these compounds wrap around chains of lysine, a basic amino acid that is a constituent of most proteins.
Working first in cell cultures, the researchers found that CLR01 was able to prevent α-synuclein from forming aggregates, prevent toxicity and even break up existing aggregates.
"The most surprising aspect of the work," Bronstein said, "is that despite the ability of the compound to bind to many proteins, it did not show toxicity or side effects to normal, functioning brain cells."
"We call this unique mechanism 'process-specific,' rather than the common protein-specific inhibition," Bitan added, meaning the compound only attacked the targeted aggregates and nothing else.
The researchers next tried their tweezers in a living animal, the zebrafish, a tropical freshwater fish commonly found in aquariums. The zebrafish is a popular animal for research because it is easily manipulated genetically, develops rapidly and is transparent, making the measurement of biological processes easier.
Using a transgenic zebrafish model for Parkinson's disease, the researchers added CLR01 and used fluorescent proteins to track the tweezer's effect on the aggregations. They found that, just as in cell cultures, CLR01 prevented α-synuclein aggregation and neuronal death, thus stopping the progression of the disorder in the living animal model.
Being able to prevent α-synuclein from aggregating, prevent toxicity and break up existing aggregates is a very encouraging result, but still, at the end of the day, "we've only stopped Parkinson's in zebrafish," Bronstein said.
"Nonetheless," he said, "all of these benefits of CLR01 were found without any evidence of toxicity. And taken together, CLR01 holds great promise as a new drug that can slow or stop the progression of Parkinson's and related disorders. This takes us one step closer to a cure."
The researchers are already studying CLR01 in a mouse model of Parkinson's and say they hope this will lead to human clinical trials.
Other authors of the study included Shubhangi Prabhudesai, Sharmistha Sinha, Aida Attar, Aswani Kotagiri, Arthur G. Fitzmaurice, Ravi Lakshmanan, Magdalena I. Ivanova, Joseph A. Loo and Mark Stahl, all of UCLA, and Frank-Gerrit Klärner and Thomas Schrader of the University of DuisburgEssen in Germany.
Provided by
University of California Los Angeles
-
SUMO defeats protein aggregates that typify Parkinson's disease
Jul 11, 2011 |
not rated yet |
0
-
Researchers find new clues about protein linked to Parkinson's disease
Jun 17, 2011 |
not rated yet |
0
-
New research reveals how alpha-synuclein interacts with cell membranes in Parkinson's disease
Jan 18, 2012 |
not rated yet |
0
-
Seeds of destruction in Parkinson's disease: Spread of diseased proteins kills neurons
Oct 05, 2011 |
not rated yet |
0
-
Lessons from yeast: A possible cure for Parkinson's disease?
Aug 14, 2008 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Enthalpy of reaction
3 hours ago
-
Harmonic oscillation problem -Dancing pot
4 hours ago
-
Ultracapacitor to power electromagnet?
5 hours ago
-
Confusion in Electro Statics
5 hours ago
-
simple gravity question
6 hours ago
-
I need help understanding the Fourier components of a square wave
8 hours ago
- More from Physics Forums - Classical Physics
More news stories
Diabetes drug tested in Parkinson's disease patients
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the ...
Parkinson's & Movement disorders
34 minutes ago |
not rated yet |
0
Faulty energy production in brain cells leads to disorders ranging from Parkinson's to intellectual disability
Neuroscientist Patrik Verstreken of VIB (Flanders Institute for Biotechnology) and KU Leuven has shown for the first time that dysfunctional mitochondria in brain cells can lead to learning disabilities. The link between ...
Parkinson's & Movement disorders
May 17, 2013 |
4 / 5 (2) |
0
Unleashing the watchdog protein
McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson's disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The ...
Parkinson's & Movement disorders
May 09, 2013 |
5 / 5 (1) |
0
|
Could eating peppers prevent Parkinson's? Dietary nicotine may hold protective key
New research reveals that Solanaceae—a flowering plant family with some species producing foods that are edible sources of nicotine—may provide a protective effect against Parkinson's disease. The study appearing today ...
Parkinson's & Movement disorders
May 09, 2013 |
not rated yet |
0
Study reveals probable role of Parkinson's protein in healthy brain
(Medical Xpress)—Researchers at the Stanford University School of Medicine have exposed the possible function, in the healthy brain, of a mysterious molecule that has been strongly implicated in Parkinson's ...
Parkinson's & Movement disorders
May 01, 2013 |
5 / 5 (3) |
0
|
First long-term study reveals link between childhood ADHD and obesity
A new study conducted by researchers at the Child Study Center at NYU Langone Medical Center found men diagnosed as children with attention-deficit/hyperactivity disorder (ADHD) were twice as likely to be obese in a 33-year ...
New study finds blind people have the potential to use their 'inner bat' to locate objects
New research from the University of Southampton has shown that blind and visually impaired people have the potential to use echolocation, similar to that used by bats and dolphins, to determine the location of an object.
Germ-fighting vaccine system makes great strides in delivery
A novel vaccine study from South Dakota State University (SDSU) will headline the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference ...
Women with severe injuries are less likely than men to be treated in a trauma center
Women are less likely than men to receive care in a trauma center after severe injury, according to a new study of almost 100,000 Canadian patients.
Neurons that can multitask greatly enhance the brain's computational power, study finds
Over the past few decades, neuroscientists have made much progress in mapping the brain by deciphering the functions of individual neurons that perform very specific tasks, such as recognizing the location ...
Impossible to predict outcome in China's bird flu outbreak, WHO says
It is impossible to predict the evolution of China's human H7N9 bird flu outbreak as researchers are still trying to understand the source of human transmission, the head of the World Health Organisation said Monday.